CytomX Therapeutics Announces FDA Acceptance of IND for CTLA-4 Probody Therapeutic

November 28, 2017

CytomX Therapeutics (Nasdaq: CTMX) announced that Bristol-Myers Squibb has received acceptance of the Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for a CTLA-4-directed Probody™ therapeutic. CTLA-4, the clinically validated target of the Bristol-Myers Squibb checkpoint inhibitor Yervoy® (ipilimumab), is the first target to advance into the clinic under the companies’ strategic collaboration formed in May 2014. The IND acceptance results in a $10 million milestone payment to CytomX.

“Immune checkpoint inhibitors are making a profound impact in the treatment of people with cancer,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics. “By localizing antibody binding and therapeutic activity to the tumor microenvironment, our goal with Probody therapeutics is to deliver the same or potentially greater potency as first-generation checkpoint inhibitors, while reducing unwanted side effects. We are excited to see the CTLA-4 Probody advancing into the clinic and look forward to additional progress in our foundational alliance with Bristol-Myers Squibb.”